Physician profile
Laura Risley
NPI 1154612901
$2,635.89
in general payments reported to CMS, 2019-2025
28 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.59 · 2022: $143 · 2023: $17.00 · 2024: $1,071 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $502.84 | 2024-2025 | Briviact, Fintepla, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $408.81 | 2024-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Neurelis, INC. | $178.93 | 2024-2025 | Valtoco |
| Boston Scientific Corporation | $143.36 | 2022 | |
| Lundbeck LLC | $139.69 | 2024-2025 | Vyepti |
| Tanabe Pharma America, INC. | $128.77 | 2024-2025 | Radicava |
| Sk Life Science, INC. | $115.21 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $104.46 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $103.59 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $101.63 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $82.50 | 2024-2025 | |
| Tonix Medicines, INC. | $77.64 | 2024-2025 | Zembrace Symtouch |
| Amneal Pharmaceuticals LLC | $73.17 | 2024-2025 | Crexont, Rytary |
| Merz Pharmaceuticals, LLC | $68.24 | 2024-2025 | Xeomin, Inbrija |
| Pfizer INC. | $57.00 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $48.48 | 2025 | Nuplazid |
| Biogen, INC. | $36.84 | 2025 | Spinraza, Qalsody |
| Amylyx Pharmaceuticals, INC. | $35.79 | 2023-2024 | Relyvrio |
| Lilly USA, LLC | $33.73 | 2024 | Emgality, Reyvow |
| Janssen Biotech, INC. | $32.91 | 2025 | |
| Springworks Therapeutics, INC. | $32.75 | 2024-2025 | Gomekli |
| Medtronic Vascular, INC. | $20.59 | 2019 | |
| Livanova USA, INC. | $20.57 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| W. L. Gore & Associates, INC. | $20.47 | 2024 | Gore Cardioform Septal Occluder |
| Novocure INC. | $19.20 | 2025 | Optune Gio |
| Electromed, INC. | $18.22 | 2024 | Smartvest |
| Merck Sharp & Dohme LLC | $16.37 | 2024 | Welireg |
| Astrazeneca Pharmaceuticals Lp | $14.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Risley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.